                         SEQUENCE LISTING

<110>  BicycleTX Limited
 
<120>  MODIFIED MULTIMERIC BICYCLIC PEPTIDE LIGANDS

<130>  BIC-C-P2614PCT

<150>  62/885,947
<151>  2019-08-13

<150>  PCT/GB2020/051831
<151>  2020-07-30

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is Nle

<400>  1

Cys Ile Glu Glu Gly Gln Tyr Cys Phe Ala Asp Pro Tyr Xaa Cys 
1               5                   10                  15  


<210>  2
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  2

Cys Ile Glu Glu Gly Gln Tyr Cys Phe Ala Asp Pro Tyr Met Cys 
1               5                   10                  15  


<210>  3
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Xaa is dK(PYA)

<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is Nle

<400>  3

Cys Ile Glu Glu Xaa Gln Tyr Cys Phe Ala Asp Pro Tyr Xaa Cys 
1               5                   10                  15  


<210>  4
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is Nle

<400>  4

Cys Ile Glu Glu Lys Gln Tyr Cys Phe Ala Asp Pro Tyr Xaa Cys 
1               5                   10                  15  


<210>  5
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Xaa is K(PYA)

<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is Nle

<400>  5

Cys Ile Glu Glu Xaa Gln Tyr Cys Phe Ala Asp Pro Tyr Xaa Cys 
1               5                   10                  15  


<210>  6
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  Xaa is tBuAla

<220>
<221>  Xaa
<222>  (4)..(4)
<223>  Xaa is K(PYA)

<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is Nle

<400>  6

Cys Xaa Pro Xaa Ala Pro Tyr Cys Phe Ala Asp Pro Tyr Xaa Cys 
1               5                   10                  15  


<210>  7
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  Xaa is tBuAla

<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Xaa is D-Lys(PYA)

<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is Nle

<400>  7

Cys Xaa Pro Glu Xaa Pro Tyr Cys Phe Ala Asp Pro Tyr Xaa Cys 
1               5                   10                  15  


<210>  8
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (3)..(3)
<223>  Xaa is 1Nal

<220>
<221>  Xaa
<222>  (7)..(7)
<223>  Xaa is HArg

<220>
<221>  Xaa
<222>  (13)..(13)
<223>  Xaa is HyP

<400>  8

Cys Pro Xaa Asp Cys Met Xaa Asp Trp Ser Thr Pro Xaa Trp Cys 
1               5                   10                  15  


<210>  9
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  Xaa is HyP

<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is HArg

<400>  9

Cys Xaa Leu Val Asn Pro Leu Cys Leu His Pro Asp Trp Xaa Cys 
1               5                   10                  15  


<210>  10
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  Xaa is HyP

<220>
<221>  Xaa
<222>  (12)..(12)
<223>  Xaa is d1Nal

<400>  10

Cys Xaa Leu Val Asn Pro Leu Cys Leu Glu Pro Xaa Trp Thr Cys 
1               5                   10                  15  


